Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$12.43 USD
+0.11 (0.89%)
Updated Oct 28, 2025 04:00 PM ET
After-Market: $12.42 -0.01 (-0.08%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Fundamental Charts
About Dividend Yield (TTM)
Monte Rosa Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
GLUE 12.43 +0.11(0.89%)
Will GLUE be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for GLUE
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Certara, Inc. (CERT) Q2 Earnings Miss Estimates
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
Other News for GLUE
GLUE makes New 52 Week Closing High on October 27
Monte Rosa Therapeutics Advances MRT-2359 in MYC-Driven Cancer Study
Monte Rosa Therapeutics Advances with MRT-8102: A Promising Phase 1 Study
New 52 Week Closing High appears for GLUE after 7.32% move
Is GLUE gaining bullish strength? Pocket Pivot shows up after rallying 11.02%